After shedding electronics and aramids, “New DuPont” is being re-rated as a focused specialty materials margin compounder—anchored in healthcare and water, with aerospace and AI-data-center industrial tailwinds.
Overview
By May 2026, DuPont has largely completed its multi-year de-conglomeration and emerged as a leaner “New DuPont” centered on Healthcare & Water Technologies and Diversified Industrials. The transformation included the tax-free spin of Electronics into Qnity (Nov 2025) and the sale of the Aramids business (Kevlar/Nomex) to Arclin (Apr 2026) for $1.8B gross consideration (including ~$1.2B pre-tax cash). Q1 2026 provides the first clean proof-point of the new operating model: continuing-ops sales rose to $1.681B (+4% YoY), operating EBITDA climbed to $414M (+15%), margin expanded 230 bps to 24.6%, and adjusted EPS jumped to $0.55 (+53%), prompting a “beat-and-raise” for FY2026 (sales $7.155–$7.215B; EPS $2.35–$2.40). The thesis centers on specialty-driven margin compounding, disciplined capital returns, and a market multiple re-rating—tempered by PFAS legacy liabilities and geopolitics/logistics risks.